AMP adds to its NBRV and VSAR positions


Today AMP increased its positions in Nabriva Therapeutics (NBRV) and Versartis (VSAR).

NBRV has a down day (-20%) and AMP sees a good buying opportunity ahead of NBRV's binary event of a Phase 3 readout for Lefamulin.


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon